NSI-189 Free Base Powder

Buy NSI-189 Free Base Powder Online

NSI-189 Free Base is the non-phosphate form of NSI-189, a small-molecule compound developed to investigate neurogenesis and hippocampal function. The active NSI-189 molecule is the basis of the clinical research conducted with its phosphate salt.

Product Information

The clinical development of NSI-189 primarily used NSI-189 phosphate, including Phase 1B and Phase 2 randomized trials. The free-base form represents the same active molecular entity without the phosphate salt, but its pharmacokinetic and formulation characteristics should not automatically be assumed identical.

How It Works

NSI-189 was developed as a neurogenic compound intended to influence neuronal growth and hippocampal function. Unlike traditional antidepressants, its proposed activity does not center on direct monoamine reuptake inhibition.

POTENTIAL BENEFITS

1. Neurogenesis Research

NSI-189 is particularly notable for its focus on neurogenesis and hippocampal biology. This mechanism has made it an important research compound for investigating how neuronal growth may influence cognition and mood.

2. Cognitive Research

Clinical trials included cognitive and physical-functioning assessments, with some exploratory improvements observed during early development.

3. Mood-Related Research

NSI-189 was investigated in patients with major depressive disorder. Although Phase 2 results did not establish superiority on the primary depression endpoint, some secondary outcomes showed potential activity.

4. Hippocampal Function

The compound's development was based in part on the relationship between hippocampal neurogenesis and cognitive and emotional function, giving NSI-189 a distinctive neuroscience research profile.

Dosage

Published human trials used NSI-189 phosphate, not a separately validated free-base dosing protocol. Phase 2 studies tested 40 and 80 mg/day of the phosphate form. These doses should not automatically be treated as equivalent dosing for a free-base formulation.

Side Effects

The human safety profile is limited to clinical development of NSI-189 phosphate. Potential CNS and systemic adverse effects remain incompletely characterized for separately formulated free-base material.

References

1. Fava M, et al. A Phase 1B, randomized, double blind, placebo-controlled, multiple-dose escalation study of NSI-189 phosphate, a neurogenic compound, in depressed patients. Mol Psychiatry. 2016;21(10):1372-1380. PMID: 26643541. PubMed
2. Papakostas GI, et al. A phase 2, double-blind, placebo-controlled study of NSI-189 phosphate, a neurogenic compound, among outpatients with major depressive disorder. Mol Psychiatry. 2020;25(7):1569-1579. PMID: 30626911. PubMed

Note: BehemothLabz does not sell this product. Purchase links on this page may direct you to third-party suppliers through affiliate links.

Please click here to see how purchases actually work on this site.